


INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference	FOR FURTHER see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
A000005	ACTION	
International application No.	International filing date (day/month/year)	(Earliest) Priority Date (day/month/year)
PCT/EP 00/09858	05/10/2000	07/10/1999
Applicant		
WARNER-LAMBERT COMPANY et	t al.	
This International Search Report has been	en prepared by this International Searching Au	thority and is transmitted to the applicant
according to Article 18. A copy is being t	ransmitted to the International Bureau.	
The later action of Course Board consist	s of a total of 3 sheets.	
This International Search Report consist X It is also accompanied b	y a copy of each prior art document cited in thi	s report.
Basis of the report	- ·	
a. With regard to the language, the language in which it was filed, un	e international search was carried out on the bankers otherwise indicated under this item.	asis of the international application in the
the international search Authority (Rule 23.1(b)).	was carried out on the basis of a translation of	the international application furnished to this
 b. With regard to any nucleotide a was carried out on the basis of the 		international application, the international search
·	tional application in written form.	•
filed together with the in	ternational application in computer readable for	rm.
furnished subsequently	to this Authority in written form.	
furnished subsequently	to this Authority in computer readble form.	
	ubsequently furnished written sequence listing as filed has been furnished.	does not go beyond the disclosure in the
the statement that the in furnished	formation recorded in computer readable form	is identical to the written sequence listing has been
Turnished		
2. Certain claims were fo	und unsearchable (See Box I).	
3. Unity of invention is la	cking (see Box II).	
4. With regard to the title ,		
	submitted by the applicant.	
	lished by this Authority to read as follows:	
the text has been established	indica by uno riddionly to road do tenerro.	
	•	
E With regard to the ehetrant		,
5. With regard to the abstract,	existent by the applicant	
the text has been estab	submitted by the applicant. lished, according to Rule 38.2(b), by this Autho he date of mailing of this international search re	ority as it appears in Box III. The applicant may, eport, submit comments to this Authority.
6. The figure of the drawings to be pu	iblished with the abstract is Figure No.	
as suggested by the ap		None of the figures.
	ailed to suggest a figure.	<u> </u>
	er characterizes the invention.	
		•

INTERNATIONAL SEARCH REPORT



A. CLASSIFICATION OF SUBJECT MATTER IPC 7 A61K31/195 A61k A61K31/40 A61P25/04 A61K31/404 A61P25/02 //(A61K31/40,31:195) A61K45/06 According to International Patent Classification (IPC) or to both national classification and IPC B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) A61P IPC 7 A61K Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practical, search terms used) WPI Data, PAJ, EPO-Internal, MEDLINE, EMBASE, BIOSIS, CHEM ABS Data C. DOCUMENTS CONSIDERED TO BE RELEVANT Relevant to claim No. Citation of document, with indication, where appropriate, of the relevant passages Category 1 - 18FIELD M J ET AL: "Involvement of the Α central tachykinin NK1 receptor during maintenance of mechanical hypersensitivity induced by diabetes in the rat" JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 285, no. 3, 1998, pages 1226-1232, XP000973157 cited in the application see "discussion" 1 - 18"CP-99,994, a nonpeptide MCLEAN S ET AL: Α antagonist of the tachykinin NK1 receptor" REGULATORY PEPTIDES vol. 46, no. 1-2, 1993, pages 329-331, XP000972928 see the final sentence of the "discussion" Further documents are listed in the continuation of box C. Patent family members are listed in annex. Special categories of cited documents: *T* later document published after the international filing date or priority date and not in conflict with the application but *A* document defining the general state of the art which is not considered to be of particular relevance cited to understand the principle or theory underlying the invention earlier document but published on or after the international "X" document of particular relevance; the claimed invention filing date cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another "Y" document of particular relevance; the claimed invention citation or other special reason (as specified) cannot be considered to involve an inventive step when the document referring to an oral disclosure, use, exhibition or document is combined with one or more other such docu ments, such combination being obvious to a person skilled document published prior to the international filing date but later than the priority date claimed "&" document member of the same patent family Date of mailing of the international search report Date of the actual completion of the international search 07/02/2001 30 January 2001 Authorized officer Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Pilling, S Fax: (+31-70) 340-3016

3

INTERNATIONAL SEARCH REPORT



T/EP 00/09858

A BRYANS JUSTIN S ET AL: "3-substituted GABA analogs with central nervous system activity: A review." MEDICINAL RESEARCH REVIEWS, vol. 19, no. 2, March 1999 (1999–03), pages 149–177, XP000972932 ISSN: 0198–6325 abstract P,X FIELD M J ET AL: "Gabapentin and the NK1 receptor antagonist CI-1021 act synergistically to block allodynia induced in a rat model of neuropathic pain." BRITISH JOURNAL OF PHARMACOLOGY, vol. 129, no. Proceedings Supplement, January 2000 (2000–01), page 79P XP000972934 Meeting of the British Pharmacological Society; Cambridge, England, UK; January 05–07, 2000 ISSN: 0007–1188 abstract	im No
GABA analogs with central nervous system activity: A review." MEDICINAL RESEARCH REVIEWS, vol. 19, no. 2, March 1999 (1999-03), pages 149-177, XP000972932 ISSN: 0198-6325 abstract P,X FIELD M J ET AL: "Gabapentin and the NK1 receptor antagonist CI-1021 act synergistically to block allodynia induced in a rat model of neuropathic pain." BRITISH JOURNAL OF PHARMACOLOGY, vol. 129, no. Proceedings Supplement, January 2000 (2000-01), page 79P XP000972934 Meeting of the British Pharmacological Society; Cambridge, England, UK; January 05-07, 2000 ISSN: 0007-1188	IIII 140.
receptor antagonist CI-1021 act synergistically to block allodynia induced in a rat model of neuropathic pain." BRITISH JOURNAL OF PHARMACOLOGY, vol. 129, no. Proceedings Supplement, January 2000 (2000-01), page 79P XP000972934 Meeting of the British Pharmacological Society; Cambridge, England, UK; January 05-07, 2000 ISSN: 0007-1188	
austract	
· · · · · · · · · · · · · · · · · · ·	

3